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Abstract
Background: HCV exhibits a high genetic diversity and is classified into 7 genotypes which are further divided into 86
confirmed subtypes. However, there are multiple isolates with unassigned subtypes. We aimed to amplify and
characterize the full-length genome sequence of an HCV genotype 1 (HCV-1) divergent isolate (DE/17–0414) in Germany.
Methods: The HCV infection was detected in an HIV-1-positive German female within an HCV/HIV-coinfection study
using a commercially available antigen-antibody HCV ELISA kit and confirmed by an in-house quantitative real-time RT-
PCR assay. Preliminary genotyping was done by sequencing and phylogenetic analysis on partial NS5B region. The full-
length genome sequence was determined by consensus RT-PCR assays. Resistance-associated substitutions (RASs) were
analyzed using the web-based tool Geno2pheno[HCV].
Results: Partial NS5B region of the isolate DE/17–0414 showed more than 95% identity to 73–08460349-1 l and HCV_Fr_
003 from France and QC316 from Canada. Full-length genome analysis of the DE/17–0414 strain showed 91.8% identity
to QC316 but less than 79.6% to other HCV-1 strains. Phylogenetic analyses demonstrated that DE/17–0414, 73–
08460349-1 l, HCV_Fr_003, and QC316 formed a separate subcluster within HCV-1. DE/17–0414 had a distinct 3 amino
acids insertion at the N-terminal of hypervariable region 1 (HVR1) within viral envelope glycoprotein 2 (E2) and several
potential antiviral RASs among the NS3 and NS5A genes.
Conclusions: We identified and analyzed an HCV-1 divergent isolate derived from an HIV-1 coinfected individual in
Germany, which will be assigned to a new HCV-subtype 1o. Our understanding of the origin and transmission dynamics
of this new subtype 1o requires further assessments from patients worldwide.
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Main text
Hepatitis C virus (HCV) causes both acute and chronic
hepatitis. According to the World Health Organization
(WHO), in 2015 an estimated number of 71 million
people have been chronically HCV-infected globally [1].
Among these, approximately 4 to 5 million individuals
are coinfected with HIV [2]. HCV/HIV-coinfections are
of major public health concern, as HIV-coinfection is as-
sociated with sometimes more serious progression of
HCV-infection [2]. Since 2011, direct-acting antivirals
(DAAs) for various genotypes of HCV are available for
standard-of-care treatment. However, there is a contro-
versial discussion whether HIV-coinfection is associated
with worse response to DAA-based therapy against
chronic hepatitis C in real life than HCV-monoinfected
patients [3, 4] and the occurrence of potential HCV
resistance-associated substitutions (RASs) is correlated
with treatment failure [5]. Therefore, detection of HIV/
HCV-coinfection and monitoring of potential HCV
RASs is of clinical importance [6]. HCV is a
positive-strand RNA virus with a 9.7 kb single-stranded,
messenger-sense RNA genome. HCV exhibits a high
genetic diversity; there are 7 genotypes, further
sub-divided into 86 confirmed subtypes according to the
10th International Committee on Taxonomy of Viruses
(ICTV) report on the taxonomy of the family Flaviviri-
dae [7]. Nonetheless, a number of HCV strains are
phylogenetically divergent from previously described se-
quences, thus can only be classified into genotypes but
without subtype assignment [8]. Globally, HCV genotype
1 (HCV-1) is dominant (46.2%) and different genotype/
subtype prevalence evolves and correlates to epidemio-
logical factors [9]. In Germany, a recent study reported
that HCV-1a (35.9%) and HCV-1b (30.6%) are the most
prevalent subtypes, followed by HCV-3 (20.6%) [10].
In this work, we aimed to amplify and characterize the
full-length genome sequence of a HCV-1 divergent strain
(DE/17–0414) from an HIV-1 coinfected individual from
Germany. According to the “Protection against Infection
Act” (IfSG; §7) diagnostic laboratories in Germany report
new HIV infections anonymously to the Robert Koch In-
stitute (RKI). Approximately 60% of the reports are sub-
mitted together with a dried serum spot (DSS) sample
prepared from residual blood of the diagnosis. Antibodies
and viral RNAs are isolated from these DSS and are used
for sentinel studies (according IfSG §13) [11]. Within a
sentinel study established at the RKI, HIV/HCV coinfec-
tions are analyzed. This includes partial sequencing for
the determination of the HCV genotype. HCV-infection
was serologically identified using the Monolisa HCV Ag/
Ab ULTRA V2 kit (Bio-Rad, Marnes-la-Coquette, France).
Viral RNA from DSS was extracted by the automated
Nuclisens EasyMag platform (bioMerieux, Capronne,
France) following the manufacturer’s instructions. HCV
viral load was measured by an in-house quantitative
RT-PCR assay targeting the 5′ noncoding region (Table 1).
Preliminary HCV genotyping was done by a consensus
nested RT-PCR assay targeting a 674 base pair fragment
in the NS5B region corresponding to nt position 7962 to
8636 of H77 reference strain. After cDNA synthesis using
the Transcriptor first-strand cDNA synthesis kit (Roche
Diagnostics, Mannheim, Germany), the complete viral
genome was amplified using KAPA HiFi HotStart Ready-
Mix PCR kit (Kapa Biosystems, Boston, USA) with
HCV-1 degenerate and DE/17–0414 specific primers
(Table 1). The 5′ and 3′ sequences were determined using
5′ and 3′ rapid amplification of cDNA ends (Roche Diag-
nostics, Mannheim, Germany). HCV amplicons were se-
quenced with the BigDye Terminator version 3.1 cycle
sequencing kit (Applied Biosystems, California, USA) in
both directions. The sequencing chromatograms were
checked for overlapping multicolor peaks. Whole-genome
sequence was assembled using Geneious software version
10.0.5 (Biomatters, Auckland, New Zealand) [12]. Se-
quence identity comparisons were performed using the
BLASTn search engine (https://blast.ncbi.nlm.nih.gov).
Phylogenetic analyses were completed using the
Neighbor-Joining method with maximum composite like-
lihood nucleotide distance between coding regions and
complete deletion option in MEGA software version 7
[13], Bootstrapping was performed with 1000 replicates.
To identify possible recombination, identity plot and boot-
scan analyses of full-length sequences were performed in
the SimPlot software program version 3.5.1 with a sliding
window size of 300 nt and a step size of 15 nt increment
[14]. Potential RASs analysis among NS3, NS5A, and
NS5B regions were conducted by Geno2pheno[HCV] – a
web-based interpretation system [15]. Relative numbering
of nucleotide (nt), amino acid (aa), insertions and dele-
tions used the HCV reference isolate H77 (GenBank ac-
cession number AF009606) [16].
A 63-year-old German heterosexual female, diagnosed
with HIV-1 in 2017, was serologically positive for antigen/
antibody combination HCV test. Viral load was 1.6 × 106
IU/ml of DSS specimen. Preliminary sequence analysis
based on partial NS5B sequences demonstrated that DE/
17–0414 has an identity of 96.3% to the isolate QC316
(GenBank accession number KJ439779) from a Canadian
immigrant with an origin in Cameroon [17]. It also shows
high identities of 95.7 and 95.3% to isolates 73–
08460349-1 l (GenBank accession number KC960818) and
HCV_Fr_003 from France (GenBank accession number
GU049346), respectively [18]. However, DE/17–0414
showed less than 83.6% identity to other HCV-1 strains.
Phylogenetic analysis of representative HCV-1 to HCV-7
members of partial NS5B region suggested that DE/17–
0414 belonged to HCV-1 forming an independent
sub-cluster with HCV_Fr_003, 73–08460349-1 l, and
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QC316 (Fig. 1a). For a more comprehensive analysis of vi-
ruses belonging to the cluster, the full-length genome se-
quence of DE/17–0414 was amplified and sequenced. The
complete genome of DE/17–0414 consisted of 9359 nt ex-
cluding the polypyrimidine tract, with a G +C content of
57.9% harboring the 10 HCV prospective genomic regions
described in Table 2. The complete genome sequence of
DE/17–0414 has been deposited in GenBank under the
accession number MH885469. DE/17–0414 had the high-
est identity with the QC316 (91.8%) and less than 79.6%
with any other HCV strain. Phylogenetic reconstructions
based on the whole-genome sequences of HCV-1 strains
showed that DE/17–0414 and QC316 formed to a separ-
ate subcluster within HCV-1 (Fig. 1b). Identity plot and
bootscan analyses reflected no evidence for recombination
between different HCV genotypes or HCV-1 subtypes
(Fig. 2a and b). Intriguingly, a unique insertion of three
aa (Q-S-R) was found at the N-terminal of hypervari-
able region 1 (HVR1) within viral envelope protein 2
(E2) (Fig. 3). In addition, several HCV-1 potential
DAAs RASs including 36 L, 170 V (NS3 region) and
28M, 31M, 93H (NS5A region), were detected in
DE/17–0414 (Table 3).
The assignment of HCV into subtypes and geno-
types is based on isolates that differ by 15–25% and
by ≥30%, respectively, over their complete coding re-
gion sequence [8]. Both DE/17–0414 and QC316 ex-
hibited close to 20% identity to other known HCV
sequences. According to the ICTV criteria required
for a new HCV genotype or subtype assignment
which are: (1) one or more complete coding region
sequence(s); (2) a distinct phylogenetic group from
previously described sequences; (3) at least three epi-
demiologically unlinked isolates and (4) exclusion of
intergenotypic or intersubtypic recombination [8]. The
sequences from a total of 4 epidemiologically un-
linked isolates that show more than 95% nucleotide
identity have been identified for which the complete
genome sequence is available for two of these and the
Table 1 Primers used for HCV quantification, genotyping and
DE/17–0414 genome amplification
Primera Sequence (5′-3′) Locationb Reference
Real-time RT-PCR assay for HCV quantification




Heminested RT-PCR assay for HCV genotyping






Heminested RT-PCR assays for DE/17–0414 genome amplification























































Table 1 Primers used for HCV quantification, genotyping and
DE/17–0414 genome amplification (Continued)









aForward primer designation end with _f; reverse primer designations end
with _r
bNumbering is according to the HCV prototype strain of H77 (GenBank Acc.
No. AF009606)
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partial NS5B sequence for the remaining two. Thus,
this meets the criteria for the assignment of a new
HCV subtype 1o. Subsequently, both DE/17–0414 and
QC316 regarded as HCV-1o reference sequences.
The main observed genotypes/subtypes in Germany
are HCV-1a, 1b and 3 [10]. In contrast, genetic diver-
sity and distribution of other genotypes/subtypes are
poorly documented. However, it is known that shifts
or relative frequencies of HCV subtypes occurred in
the last decades and the approval of DAAs for
HCV-treatment is an additional factor, which will
probably influence the subtype distribution [19].
Therefore, the knowledge on the genetic diversity of
HCV is not only of epidemiological but also clinical
significance. The core protein and envelope
Fig. 1 Phylogenetic relationships of DE/17–0414. The strain designations are indicated with geno/subtype and accession number at each branch. Clades
corresponding to each genotype were supported by 100% of bootstrap replicates. Bootstrap values (> 75%) are indicated at specific nodes. Scale bars
indicate the number of nt substitutions per site. HCV-1 subtypes and the new distinct sub-cluster are indicated on the right. DE/17–0414 of this study is
highlighted in bold and red. (a) Phylogenetic analysis of representative HCV-1 strains based on 328 nt of partial NS5B sequences corresponding to nt
positions 8283 to 8610 of H77 reference strain. (b) Phylogenetic analysis of HCV-1 complete coding region sequences
Table 2 Genomic regions of DE/−17–0414
Genomic region NA numbering AA numbering











3′ UTR 9329–9359 NA
aNA for not applicable
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glycoproteins 1 and 2 constitute the structural ele-
ments of HCV [20]. The N-terminal of E2, called
HVR1, is most divergent among HCV isolates and
contributes to immune escape [21]. A distinct 3 aa
(Q-S-R) insertion at the N-terminal of HVR1 was
found in DE/17–0414 which exists in none of other
known HCV strains. Whether the insertion is
associated to HIV-coinfection and its function needs
to be further analyzed. With the approval of DAA
regimens testing HCV for RASs is clinically relevant.
Several potential RASs were detected in the NS3 and
NS5A genomic regions of DE/17–0414 on the basis
of HCV subtypes 1a and 1b [6], indicating that corre-
sponding DAAs should be avoided in this individual.
Fig. 2 Analysis of potential recombination events of the DE/17–0414. Identity Plot and BootScan analyses of (a) HCV genotypes and (b) HCV-1
subtypes. All analyses were performed with a window of 300 nt and a step size of 15 nt under Kimura 2-parameter model. Positions containing
gaps were stripped from the alignment. QC316 is highlighted in bold and red
Fig. 3 Sequence alignment of HCV-1 E1 and E2 genomic regions. The newly detected Q-S-R insertion of DE/17–0414 and HVR1 at the N-terminal
of E2 is indicated at the bottom. Absolute numbering is corresponding to aa position 364 to 420 of H77 reference strain
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In conclusion, we identified and analyzed an HCV-1 di-
vergent isolate from an HIV-1 coinfected individual in
Germany, which will be assigned to a new subtype 1o with
other three epidemiologically unrelated analogous HCV
isolates. The origin and transmission dynamics of this new
subtype needs further verification by more comprehensive
genetic analyses of HCV strains from patients worldwide.
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